Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks

Pediatric Infectious Disease Journal

Volumn 27, Issue 7, 2008, Pages 623-628

  Kosalaraksa, Pope ^a   Bunupuradah, Torsak ^b   Engchanil, Chulapan ^a   Boonrak, Pitch ^b   Intasan, Jintana ^b   Lumbiganon, Pagakrong ^a   Burger, David ^c   Ruxrungtham, Kiat ^a,d   Schutz, Malte ^e   Ananworanich, Jintanat ^b,f  

^a KHON KAEN UNIVERSITY   (Thailand)

^b THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d CHULALONGKORN UNIVERSITY   (Thailand)

^e HOFFMANN LA ROCHE INC   (United States)

^f South East Asia Research Collaboration with Hawaii ^*  (Thailand)

Author keywords

ARV; Children; Double boosted PI; HAART; Second line; VL failure

Indexed keywords

CD4 ANTIGEN; CHOLESTEROL; CREATININE; DIDANOSINE; EFAVIRENZ; GLUCOSE; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TRIACYLGLYCEROL; TUBERCULOSTATIC AGENT; VIRUS RNA; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LOPINAVIR; PROTEINASE INHIBITOR; PYRIMIDINONE DERIVATIVE; RITONAVIR;

ABDOMINAL PAIN; ARTICLE; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GINGIVITIS; GINGIVOSTOMATITIS; GLUCOSE BLOOD LEVEL; HEMOPTYSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; LUNG TUBERCULOSIS; MALE; MULTICENTER STUDY; NONHUMAN; PANCREATITIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; SCHOOL CHILD; SIDE EFFECT; STOMATITIS; THAILAND; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD; ANTIVIRAL RESISTANCE; BLOOD; BLOOD ANALYSIS; CD4 LYMPHOCYTE COUNT; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS; PROSPECTIVE STUDY; TREATMENT REFUSAL;

ANTI-HIV AGENTS; BLOOD CHEMICAL ANALYSIS; CD4 LYMPHOCYTE COUNT; CHILD; CHOLESTEROL; DRUG RESISTANCE, VIRAL; FEMALE; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; HYPERLIPIDEMIAS; MALE; PROSPECTIVE STUDIES; PYRIMIDINONES; RITONAVIR; SAQUINAVIR; THAILAND; TREATMENT REFUSAL; TRIGLYCERIDES; VIRAL LOAD;

EID: 50949083015     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31816b4539     Document Type: Article

References (68)

1. Patel KHM, Williams PL, Seegar JD, McIntosh K, Seage GR III. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents infected with HIV-1. Paper presented at: Program and abstracts of the XVI International AIDS Conference; August 13-18, 2006; Toronto, Canada. Abstract WEAB0303.
2. World Health Organization. Antiretroviral Therapy of HIV Infection in Infants and Children in Resource-Limited Settings, Towards Universal Access: Recommendations for a Public Health Approach; 2006. Available at: http://www.who.int/hiv/mediacentre/fs-2006guidelines-paediatric/en/index.html.
3. Ministry of Public Health, Thailand. National Guidelines for the Clinical Management of HIV Infection in Children and Adult. Bangkok: Ministry of Public Health; 2004.
4. Puthanakit T, Oberdorfer A, Akarathum N, et al. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program. Clin Infect Dis. 2005;41:100-107.
5. Maldarelli F. Handbook of Pediatric HIV Care. 2nd ed. Cambridge, UK: Cambridge University Press; 2006:397-414.
6. Sharland M, di Zub GC, Ramos JT, Blanche S, Gibb DM. PENTA guidelines for the use of antiretroviral therapy in paediatric HIV infection. Pediatric European Network for Treatment of AIDS. HIV Med. 2002;3:215-226.
7. The Working Group on Antiretroviral Therapy. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Available at: www. aidsinfo.nih.gov. Accessed October 26, 2006.
8. King M, Johnson M, Youle M, et al. Antiviral Activity of Lopinavir/Ritonavir-based Regimens in Subjects with CD4 cell Counts Below 25 cells/mm3. Paper presented at: Program and Abstracts of the 10th European AIDS Clinical Society Conference; November 17-20, 2005; Dublin, Ireland. Abstract PE7.3/4.
9. Sharland M, Blanche S, Castelli G, Ramos J, Gibb DM. PENTA guidelines for the use of antiretroviral therapy. HIV Med. 2004;5:61-86.
10. Ribera E, Lopez RM, Diaz M, et al. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother. 2004;48:4256-4262.
11. Ministry of Public Health, Thailand. National Guidelines for the Clinical Management of HIV Infection in Children and Adult. Bangkok: Ministry of Public Health; In press.
12. Lolekha R, Sirivichayakul S, Siangphoe U, et al. Resistance to dual nucleoside reverse-transcriptase inhibitors in children infected with HIV clade A/E. Clin Infect Dis. 2005;40:309-312.
13. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis. 2007;44:447-452.
14. Hellinger J, Cohen C, Morris A, et al. Pilot study of saquinavir and lopinavir/ritonavir twice daily in protease inhibitor-naive HIV-positive patients. HIV Clin Trials. 2005;6:107-117.
15. Ananworanich J, Kosalaraksa P, Hill A, et al. Pharmacokinetics and 24-week Efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children. Pediatr Infect Dis J. 2005;24:874-879.
16. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-2752.
17. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med. 2006;14:125-130.
18. Delaugerre C, Teglas JP, Treluyer JM, et al. Predictive factors of virologic success in HIV-1-infected children treated with lopinavir/ritonavir. J Acquir Immune Defic Syndr. 2004;37:1269-1275.
19. Resino S, Bellon JM, Ramos JT, et al. Salvage lopinavir-ritonavir therapy in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2004;23:923-930.
20. Ramos JT, De Jose MI, Duenas J, et al. Safety and antiviral response at 12 months of lopinavir/ritonavir therapy in human immunodeficiency virus-1-infected children experienced with three classes of antiretrovirals. Pediatr Infect Dis J. 2005;24:867-873.
21. Bartlett JA, Fath MJ, Demasi R, et al. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS. 2006;20:2051-2064.
22. Murphy RL, da Silva B, McMillan F, et al. Seven-year follow-up of a lopinavir/ritonavir (LPV/r)-based regimen in antiretroviral (ARV)-naive subjects -Abstract PE7.9/3-. Paper presented at: 10th European AIDS Conference; November 17-20, 2005; Dublin.
23. Ananworanich J, Hirschel B, Sirivichayakul S, et al. Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir. Antivir Ther. 2006;11:631-635.
24. Leonard EG, McComsey GA. Metabolic complications of antiretroviral therapy in children. Pediatr Infect Dis J. 2003;22:77-84.
25. Taylor P, Worrell C, Steinberg SM, et al. Natural history of lipid abnormalities and fat redistribution among human immunodeficiency virus-infected children receiving long-term, protease inhibitor-containing, highly active antiretroviral therapy regimens. Pediatrics. 2004;114: e235-e242.
26. Saez-Llorens X, Violari A, Deetz CO, et al. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2003; 22:216-224.
27. Ananworanich J, Hill A, Siangphoe U, et al. A prospective study of Efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients. Antivir Ther. 2005;10:761-767.
28. Autar RS, Boffito M, Hassink E, et al. Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients. J Antimicrob Chemother. 2005;56:908-913.
29. Boyd M, Mootsikapun P, Burger D, et al. Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients. Antivir Ther. 2005;10:301-307.
30. 629-635
31. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331:1173-1180.
32. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA. 2004;292:251-265.
33. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society- USA panel. JAMA. 2006;296:827-843.
34. O'Brien WA, Hartigan PM, Daar ES, Simberkoff MS, Hamilton JD. Changes in plasma HIV RNA levels and CD4- lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA Cooperative Study Group on AIDS. Ann Intern Med. 1997;126: 939-945.
35. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337: 734-739.
36. Mofenson LM, Korelitz J, Meyer WA 3rd, et al. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1- infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. J Infect Dis. 1997;175:1029-1038.
37. Palumbo PE, Raskino C, Fiscus S, et al. Predictive value of quantitative plasma HIV RNA and CD4- lymphocyte count in HIV-infected infants and children. JAMA. 1998;279:756-761.
38. Valentine ME, Jackson CR, Vavro C, et al. Evaluation of surrogate markers and clinical outcomes in two-year follow-up of eighty-six human immunodeficiency virus-infected pediatric patients. Pediatr Infect Dis J. 1998;17:18-23.
39. Shearer WT, Quinn TC, LaRussa P, et al. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. N Engl J Med. 1997;336:1337-1342.
40. De Rossi A. Virological and immunological response to antiretroviral therapy in HIV-1 infected children: genotypic and phenotypic assays in monitoring virological failure. New Microbiol. 2004;27:45-50.
41. Naver L, Ehrnst A, Belfrage E, et al. Long-term pattern of HIV-1 RNA load in perinatally infected children. Scand J Infect Dis. 1999;31:337-343.
42. Hughes MD, Stein DS, Gundacker HM, Valentine FT, Phair JP, Volberding PA. Within-subject variation in CD4- lymphocyte count in asymptomatic human immunodeficiency virus infection: implications for patient monitoring. J Infect Dis. 1994;169:28-36.
43. Wade AM, Ades AE. Incorporating correlations between measurements into the estimation of age-related reference ranges. Stat Med. 1998;17: 1989-2002.
44. Stein DS, Korvick JA, Vermund SH. CD4- lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: a review. J Infect Dis. 1992;165:352-363.
45. Mandy FF, Nicholson JK, McDougal JS. Guidelines for performing single-platform absolute CD4- T-cell determinations with CD45 gating for persons infected with human immunodeficiency virus. Centers for Disease Control and Prevention. MMWR Recomm Rep. 2003;52:1-13.
46. Lyamuya EF, Kagoma C, Mbena EC, et al. Evaluation of the FAC-Scount, TRAx CD4 and Dynabeads methods for CD4 lymphocyte determination. J Immunol Methods. 1996;195:103-112.
47. Sherman GG, Galpin JS, Patel JM, Mendelow BV, Glencross DK. CD4- T cell enumeration in HIV infection with limited resources. J Immunol Methods. 1999;222:209-217.
48. Cassens U, Gohde W, Kuling G, et al. Simplified volumetric flow cytometry allows feasible and accurate determination of CD4 T lymphocytes in immunodeficient patients worldwide. Antivir Ther. 2004;9: 395-405.
49. Diagbouga S, Chazallon C, Kazatchkine MD, et al. Successful implementation of a low-cost method for enumerating CD4- T lymphocytes in resource-limited settings: the ANRS 12-26 study. AIDS. 2003;17: 2201-2208.
50. Andiman WA, Simpson BJ, Olson B, Dember L, Silva TJ, Miller G. Rate of transmission of human immunodeficiency virus type 1 infection from mother to child and short-term outcome of neonatal infection. Results of a prospective cohort study. Am J Dis Child. 1990;144:758-766.
51. Simpson BJ, Andiman WA. Difficulties in assigning human immunodeficiency virus-1 infection and seroreversion status in a cohort of HIV-exposed in children using serologic criteria established by the Centers for Disease Control and Prevention. Pediatrics. 1994;93:840-842.
52. Centers for Disease Control (CDC). Classification system for human immunodeficiency virus (HIV) infection in children under 13 years of age. MMWR Morb Mortal Wkly Rep. 1987;36:225-230;235-236.
53. Dunn DT, Brandt CD, Krivine A, et al. The sensitivity of HIV-1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intra-uterine and intra-partum transmission. AIDS. 1995;9: F7-F11.
54. Littell RC, Henry PR, Ammerman CB. Statistical analysis of repeated measures data using SAS procedures. J Anim Sci. 1998;76:1216-1231.
55. Use of total lymphocyte count for informing when to start antiretroviral therapy in HIV-infected children: a meta-analysis of longitudinal data. Lancet. 2005;366:1868-1874.
56. HIV Paediatric Prognostic Markers Collaborative Study. Predictive value of absolute CD4 cell count for disease progression in untreated HIV-1-infected children. AIDS. 2006;20:1289-1294.
57. Pantaleo G, Graziosi C, Fauci AS. New concepts in the immunopatho-genesis of human immunodeficiency virus infection. N Engl J Med. 1993;328:327-335.
58. Nkengasong JN, Adje-Toure C, Weidle PJ. HIV antiretroviral drug resistance in Africa. AIDS Rev. 2004;6:4-12.
59. Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach. Executive summary. IAPAC. 2002;8:168-175.
60. Colebunders R, Moses KR, Laurence J, et al. A new model to monitor the virological Efficacy of antiretroviral treatment in resource-poor countries. Lancet Infect Dis. 2006;6:53-59.
61. Kent DM, McGrath D, Ioannidis JP, Bennish ML. Suitable monitoring approaches to antiretroviral therapy in resource-poor settings: setting the research agenda. Clin Infect Dis. 2003;37:S13-S24.
62. Florence E, Dreezen C, Schrooten W, et al. The role of non-viral load surrogate markers in HIV-positive patient monitoring during antiviral treatment. Int J STD AIDS. 2004;15:538-542.
63. Lugada ES, Mermin J, Kaharuza F, et al. Population-based hematologic and immunologic reference values for a healthy Ugandan population. Clin Diagn Lab Immunol. 2004;11:29-34.
64. Florence E, Lundgren J, Dreezen C, et al. Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV Med. 2003;4:255-262.
65. Rodriguez B, Sethi AK, Cheruvu VK, et al. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA. 2006;296:1498-1506.
66. European Collaborative Study. Are there gender and race differences in cellular immunity patterns over age in infected and uninfected children born to HIV-infected women? J Acquir Immune Defic Syndr. 2003;33: 635-641.
67. Bunders M, Cortina-Borja M, Newell ML. Age-related standards for total lymphocyte, CD4 and CD8 T cell counts in children born in Europe. Pediatr Infect Dis J. 2005;24:595-600.
68. European Collaborative Study. HIV-infected pregnant women and vertical transmission in Europe since 1986. AIDS. 2001;15:761-770.